227623-26-9

Basic information

• Product Name: 5-TERT-BUTYL-2-(4-METHOXY-PHENYL)-2H-PYRAZOL-3-YLAMINE
• Synonyms: 5-TERT-BUTYL-2-(4-METHOXY-PHENYL)-2H-PYRAZOL-3-YLAMINE;BUTTPARK 30\09-73;1H-Pyrazol-5-aMine, 3-(1,1-diMethylethyl)-1-(4-Methoxyphenyl)-;3-(tert-Butyl)-1-(4-Methoxyphenyl)-1H-pyrazol-5-aMine;3-tert-butyl-1-(4-methoxyphenyl)-1H-pyrazole
• CAS NO: 227623-26-9
• Molecular Formula: C₁₄H₁₉N₃O
• Molecular Weight: 245.32
• Mol File: 227623-26-9.mol
• Article Data: 21

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 5-TERT-BUTYL-2-(4-METHOXY-PHENYL)-2H-PYRAZOL-3-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-TERT-BUTYL-2-(4-METHOXY-PHENYL)-2H-PYRAZOL-3-YLAMINE(227623-26-9)
• EPA Substance Registry System: 5-TERT-BUTYL-2-(4-METHOXY-PHENYL)-2H-PYRAZOL-3-YLAMINE(227623-26-9)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 227623-26-9(Hazardous Substances Data)

Usage

General Description

5-Tert-butyl-2-(4-methoxy-phenyl)-2H-pyrazol-3-ylamine is a chemical compound with the molecular formula C14H20N2O. It is a pyrazole derivative with a tert-butyl group and a 4-methoxyphenyl group attached to the pyrazole ring. 5-TERT-BUTYL-2-(4-METHOXY-PHENYL)-2H-PYRAZOL-3-YLAMINE is commonly used as a building block in organic synthesis and drug discovery research. It has been studied for its potential pharmacological properties, including its ability to modulate the activity of certain enzymes and receptors in the body. However, further research is needed to fully understand the biological effects and potential applications of this compound.

Upstream product

• 59997-51-2 trimethylacetylacetonitrile 
• 3471-32-7 4-Methoxyphenylhydrazine 
• 19501-58-7 4-methoxyphenylhydrazine hydrochloride 

Downstream Products

• 725686-64-6 1-{3-tert-butyl-1-(4-methoxyphenyl)-1H-pyrazol-5-yl}-3-(4-bromophenyl)urea 
• 869663-58-1 4-(5-amino-3-tert-butyl-pyrazol-1-yl)-phenol 
• 950643-42-2 6-(6-chloro-pyrimidin-4-yloxy)naphthalene-1-carboxylic acid [5-tert-butyl-2-(4-methoxy-phenyl)-2H-pyrazol-3-yl]-amide 
• 950643-48-8 6-(6-chloro-pyrimidin-4-yloxy)-isoquinoline-1-carboxylic acid [5-tert-butyl-2-(4-methoxy-phenyl)-2H-pyrazol-3-yl]amide 
• 1338814-51-9 N-(4-((4-(3-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)pyridin-2-yl)-2-methoxyacetamide 
• 1338814-54-2 1-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)-3-(4-(2-(3-cyclopropylureido)pyridin-4-yloxy)naphthalen-1-yl)urea 
• 1338814-57-5 N-(4-((4-(3-(3-tert-butyl-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)ureido)naphthalen-1-yl)oxy)pyridin-2-yl)morpholine-4-carboxamide 
• 1338814-58-6 N-(4-(4-(3-(3-tert-butyl-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)ureido)naphthalen-1-yloxy)pyridin-2-yl)-4-methylpiperazine-1-carboxamide 
• 1338814-52-0 N-(4-(4-(3-(3-tert-butyl-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)ureido)naphthalen-1-yloxy)pyridin-2-yl)-2-hydroxyacetamide 
• 1337930-81-0 1-(3-tert-butyl-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)-3-(2,3-dichloro-4-(2-(3-methylureido)pyridin-4-yl)methoxyphenyl)urea 
• 1337930-83-2 N-(4-((4-(3-(3-tert-butyl-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)ureido)-2,3-dichlorophenoxy)methyl)pyridin-2-yl)pyrrolidine-1-carboxamide 
• 1337930-86-5 N-(4-(4-(3-(3-tert-butyl-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)ureido)-2,3-dichlorophenoxy)pyrimidin-2-yl)-2-methoxyacetamide 
• 1337930-89-8 N-(4-((4-(3-(3-tert-butyl-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)ureido)-2,3-dichlorophenylthio)methyl)pyridin-2-yl)-2-methoxyacetamide 
• 1337930-72-9 N-methyl-N'-(4-(4-(3-(3-tert-butyl-1-p-anisyl-1H-pyrazol-5-yl)ureido)-2,3-dichlorophen-1-yloxy)pyridin-2-yl)urea 

Relevant articles and documents

POLYAROMATIC UREA DERIVATIVES AND THEIR USE IN THE TREATMENT OF MUSCLE DISEASES

The current invention provides urea derivatives, in particular compounds having the core structure heteroaryl-NH-CO-NH-aryl-O- heteroaryl, for use in treating, ameliorating, delaying, curing and/ or preventing a disease or condition associated with muscle cells and/or satellite cells, such as Duchenne muscular dystrophy, Becker muscular dystrophy, cachexia or sarcopenia.

Pyrazole C-region analogues of 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as potent TRPV1 antagonists

A series of 1-substituted 3-(t-butyl/trifluoromethyl)pyrazole C-region analogues of 2-(3-fluoro-4-methylsulfonamidophenyl)propanamides were investigated for hTRPV1 antagonism. The structure activity relationship indicated that the 3-chlorophenyl group at the 1-position of pyrazole was the optimized hydrophobic group for antagonistic potency and the activity was stereospecific to the S-configuration, providing exceptionally potent antagonists 13S and 16S with Ki(CAP) = 0.1 nM. Particularly significant, 13S exhibited antagonism selective for capsaicin and NADA and not for low pH or elevated temperature. Both compounds also proved to be very potent antagonists for rTRPV1, blocking in vivo the hypothermic action of capsaicin, consistent with their in vitro mechanism. The docking study of compounds 13S and 16S in our hTRPV1 homology model indicated that the binding modes differed somewhat, with that of 13S more closely resembling that of GRT12360.

Biophysical investigation and conformational analysis of p38α kinase inhibitor doramapimod and its analogues

Doramapimod (BIRB 796) is a potent inhibitor of p38α mitogen-activated protein kinase. It contains an aryl-pyrazole scaffold as a pharmacophore critical for binding. The aryl-pyrazole scaffold is not planar and adopts an out-of-plane conformation, which is described by the torsion angle θ. In this letter, we report the chemical synthesis and biophysical characterization of different analogues of doramapimod (3-12) exhibiting distinctly different aryl-pyrazole torsion angle θ values. The torsion angle θ values of the synthesized analogues (3-6) were determined by crystal structural analysis and the binding affinities to p38α kinase investigated by microscale thermophoresis. Our results unveil a clear correlation between kinase binding and the torsion angle θ of tested doramapimod analogues, highlighting the importance of inhibitor conformation for protein binding.